- Global Pharma News & Resources

Almirall seeks novel targets for skin health

  • AlmirallShare new call is looking for novel targets and concepts which may form the basis for new medicines in dermatological diseases
  • Universities, research centers, start-ups, biotechs and pharmaceutical companies worldwide with an interest in R&D are invited to send their proposals for consideration through
  • Almirall will provide scientific support and funding, up to 100,000€, to the selected proposals

AlmirallShare, the open innovation platform of Almirall, S.A. (ALM) launches today a new call with the aim of finding novel targets and concepts in the treatment of dermatological diseases. Targets of interest may be proteins or nucleic acids whose function can be modulated by a small molecule or biological therapy that have a scientific rationale in a dermatological disease. Concepts may be mechanisms, pathways, or cell players not previously linked to a disease of interest.

The call is open from October 10th, 2018 to February 28th, 2019 and is addressed to universities, research centers, start-ups, biotechs and pharma companies all over the world with an interest in pharmaceutical R&D.

Scientists from these organisations are invited to submit their proposals. All submitted projects are evaluated in a pre-defined period of time and those that are accepted are eligible for a research grant up to 100.000€. Selected proposals may also benefit from scientific support from Almirall’s team, access to Almirall’s technology platforms and pharmacological tools to assist them on target validation, and specialised advice for intellectual property matters, if requested. 

Since its launch in September 2017, AlmirallShare has drawn the attention of Scientists from universities, research centers and start-ups interested on dermatological research. About 380 scientists from all continents have subscribed to the platform and over 120  proposals have been received to date. A selection of innovative ideas were accepted and they are currently being developed.

“Given the results we had with our previous AlmirallShare calls, we are really looking forward to launch this new call. We are expecting to collaborate with experts worldwide to identify novel targets that may form the basis for new medicines. It is an opportunity for both parts, Almirall and the Research partners, to develop innovative therapies for patients suffering from dermatological diseases.” said Maribel Crespo, AlmirallShare Leader.


About AlmirallShare

AlmirallShare is an open innovation platform designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in skin health. By putting together the Science and creativity of experts around the world and Almirall’s own expertise, the AlmirallShare initiative will accelerate the generation of new treatments for skin conditions.


About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in its continuous improvement, bringing our innovative solutions where they are needed.

The company, founded 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life. Total revenues in 2017 were 755.8 million euros. More than 1,830 employees are devoted to Science.

For more information, please visit


Media contact:                                                              Investors & Corporate Communications contact:

bcw                                                                                  Almirall

Marta Gállego                                                                   Pablo Divasson del Fraile                               

Tel.: (+34) 915 31 42 67                                                     Tel.: (+34) 93 291 30 87

Editor Details

Last Updated: 17-Oct-2018